Serum uric acid levels and freezing of gait in Parkinson’s disease

被引:0
作者
Ruwei Ou
Bei Cao
Qianqian Wei
Yanbing Hou
Yaqian Xu
Wei Song
Bi Zhao
Huifang Shang
机构
[1] Sichuan University,Department of Neurology, West China Hospital
来源
Neurological Sciences | 2017年 / 38卷
关键词
Freezing of gait; Parkinson’s disease; Uric acid;
D O I
暂无
中图分类号
学科分类号
摘要
Uric acid (UA) is a natural antioxidant and iron scavenger in the human body, which has been hypothesized to exert an anti-oxidative effect in Parkinson’s disease (PD). This study aimed to investigate the relationship between serum UA levels and freezing of gait (FOG) in PD. A total of 321 Chinese PD patients with fasting serum UA evaluated were included in the cross-sectional study. Demographics, clinical features, and therapeutic regimen were collected. The Unified PD Rating Scale (UPDRS) III and Hoehn and Yahr (H and Y) stage were used to evaluate the severity of disease, and the Frontal Assessment Battery (FAB) and Montreal Cognitive Assessment (MoCA) scales were used to assess the cognitive function. Patients with FOG showed lower proportion of male, longer disease duration, lower body mass index, lower concentrations of serum UA, higher total levodopa equivalent daily dosage, higher UPDRS III score, greater median H and Y stage, lower scores of FAB and MoCA, and higher frequencies of motor fluctuation, dyskinesia, falls, and festination compared to patients without FOG (P < 0.05). The binary logistic regression model indicated that high UPDRS III score (OR = 1.049, P < 0.001), fluctuation (OR = 2.677, P = 0.035), dyskinesia (OR = 6.294, P = 0.003), festination (OR = 3.948, P < 0.001), falls (OR = 7.528, P < 0.001), and low serum UA levels (OR = 0.990, P < 0.001) were associated with FOG. Our study suggests that low serum UA concentration is associated with the occurrence of FOG in PD.
引用
收藏
页码:955 / 960
页数:5
相关论文
共 221 条
  • [11] LeWitt PA(2007)Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan Mov Dis Off J Mov Dis Soc 22 41-47
  • [12] Xu K(1967)Parkinsonism: onset, progression and mortality Neurology 17 427-442
  • [13] Eberly S(2000)The FAB: a Frontal Assessment Battery at bedside Neurology 55 1621-1626
  • [14] Watts A(2005)The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment J Am Geriatr Soc 53 695-699
  • [15] Matson WR(2009)Validation of the freezing of gait questionnaire in patients with Parkinson’s disease Mov Disord 24 655-661
  • [16] Marras C(1994)Uric acid is reduced in the substantia nigra in Parkinson’s disease: effect on dopamine oxidation Brain Res Bull 33 419-425
  • [17] Kieburtz K(2015)Association between serum uric acid and motor subtypes of Parkinson’s disease J Clin Neurosci Off J Neurosurg Soc Australas 22 1264-1267
  • [18] Rudolph A(2014)Serum uric acid concentration is linked to wearing-off fluctuation in Japanese Parkinson’s disease patients J Parkinsons Dis 4 499-505
  • [19] Bogdanov MB(2014)Is serum uric acid related to non-motor symptoms in de-novo Parkinson’s disease patients? Parkinsonism Relat Dis 20 772-775
  • [20] Schwid SR(2013)Uric acid is associated with the prevalence but not disease progression of multiple system atrophy in Chinese population J Neurol 260 2511-2515